



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 12th February, 2025

To,

The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Subject: Statement of deviation or variation in utilisation of funds raised through Preferential Issue for the quarter ended 31st December, 2024

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith the statement of deviation or variation in utilisation of funds raised through preferential issue for the quarter ended 31st December, 2024.

We request to kindly take note of the same

Thanking you

Yours faithfully

For SMS Pharmaceuticals Limited

**Thirumalesh Tumma
Company Secretary**

Statement of Deviation / Variation in utilisation of funds raised through Preferential Allotment

Name of listed entity		SMS Pharmaceuticals Limited				
Mode of Fund Raising		Preferential Issue				
Date of Raising Funds		19 th March, 2024 (Allotment of 90,00,000 convertible warrants upon receipt of 25% of the issue price at Rs.127/- per warrant)				
Amount Raised		Rs. 28,57,50,000/-				
Report filed for Quarter ended		31 st December, 2024				
Monitoring Agency		Applicable				
Monitoring Agency Name, if applicable		M/s. CARE Ratings Limited				
Is there a Deviation / Variation in use of funds raised		No				
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders		Not Applicable				
If Yes, Date of shareholder Approval		Not Applicable				
Explanation for the Deviation / Variation		Not Applicable				
Comments of the Audit Committee after review		Nil				
Comments of the auditors, if any		Nil				
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 31st December, 2024	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
The proceeds of the Preferential issue shall be utilized to meet the Capital Expenditure requirement for Expansion of production capacities in phased manner and installation of additional utility equipment's as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks. Further, it may be utilized to meet Working Capital Requirement and General Purpose also.	Not Applicable	Rs. 28,57,50,000/-	Not Applicable	Rs. 28,57,00,000/-	NIL	-




Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For SMS Pharmaceuticals Limited


Lakshmi Narayana Tammineedi
Chief Financial Officer



Place: Hyderabad

Date: 12.02.2025